September 22, 2008
Howard McLeod, PharmD, will receive the Therapeutic Frontiers Lecture Award from the American College of Clinical Pharmacy.
The award recognizes an individual who has made outstanding contributions to pharmacotherapeutics in his or her field, according to ACCP. McLeod is a Fred Eshelman Distinguished Professor and the director of the UNC Institute of Pharmacogenomics and Individualized Therapy.
McLeod will deliver his lecture, titled “The Genome as a Tool for Clinical Pharmacy,” at the 2008 ACCP Annual Meeting at 10:30 a.m. on October 19.
Among ACCP’s criteria for this award is the broad acknowledgment that the recipient is currently considered to be at the leading edge of research in the field. McLeod is internationally recognized for his many important contributions to the field of pharmacogenomics of cancer chemotherapy. McLeod is widely regarded as a leading clinical and translational investigator and has published extensively during his career.
ACCP released a quote from one of Mcleod’s nominating letters that points to his broad contributions to pharmacogenomics and therapeutics.
“Although McLeod has focused in the areas of cancer chemotherapy, it has been remarkable to see the contributions that he has also made more broadly to cardiovascular disease, anticoagulation and, indeed, how he has helped define general principles of therapeutics …. He is one of the few principal investigators in the country to receive NIH funding for a center for pharmacogenetics research … and who has been able to successfully bring together scientists from multiple fields—biostatistics, internal medicine, oncology, molecular biology, genomics—to facilitate interactions, collaborations, and make true progress in the field of pharmacogenomics.”